Clinical trial
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory…
NCT00326664 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00326664 |
|---|---|
| Title | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors |
| Official title | A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm and 11 more |
| Intervention type | Drug |
| Interventions | Cediranib Maleate |
| Enrollment | 55 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | May 17, 2006 |
| Last update posted | Mar 7, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: